• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于四面体型核酸框架的 MicroRNA-22 递呈通过调控 Wnt 通路抑制病理性新生血管形成和血管闭塞。

Tetrahedral framework nucleic acids-based delivery of MicroRNA-22 inhibits pathological neovascularization and vaso-obliteration by regulating the Wnt pathway.

机构信息

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.

Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

出版信息

Cell Prolif. 2024 Jul;57(7):e13623. doi: 10.1111/cpr.13623. Epub 2024 Mar 3.

DOI:10.1111/cpr.13623
PMID:38433462
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11216936/
Abstract

The objective of this study was to investigate the effects and molecular mechanisms of tetrahedral framework nucleic acids-microRNA22 (tFNAs-miR22) on inhibiting pathological retinal neovascularization (RNV) and restoring physiological retinal vessels. A novel DNA nanocomplex (tFNAs-miR22) was synthesised by modifying microRNA-22 (miR22) through attachment onto tetrahedral frame nucleic acids (tFNAs), which possess diverse biological functions. Cell proliferation, wound healing, and tube formation were employed for in vitro assays to investigate the angiogenic function of cells. Oxygen-induced retinopathy (OIR) model was utilised to examine the effects of reducing pathological neovascularization (RNV) and inhibiting vascular occlusion in vivo. In vitro, tFNAs-miR22 demonstrated the ability to penetrate endothelial cells and effectively suppress cell proliferation, tube formation, and migration in a hypoxic environment. In vivo, tFNAs-miR22 exhibited promising results in reducing RNV and promoting the restoration of normal retinal blood vessels in OIR model through modulation of the Wnt pathway. This study provided a theoretical basis for the further understanding of RNV, and highlighted the innovative and potential of tFNAs-miR22 as a therapeutic option for ischemic retinal diseases.

摘要

本研究旨在探讨四面体框架核酸-微小 RNA22(tFNAs-miR22)抑制病理性视网膜新生血管(RNV)和恢复生理视网膜血管的作用及分子机制。通过将 microRNA-22(miR22)修饰到具有多种生物学功能的四面体框架核酸(tFNAs)上,合成了一种新型 DNA 纳米复合物(tFNAs-miR22)。通过体外细胞增殖、划痕愈合和管形成实验研究了细胞的血管生成功能。利用氧诱导的视网膜病变(OIR)模型研究了体内减少病理性新生血管(RNV)和抑制血管闭塞的效果。体外,tFNAs-miR22 能够穿透内皮细胞,并在缺氧环境下有效抑制细胞增殖、管形成和迁移。在体内,tFNAs-miR22 通过调节 Wnt 通路,在 OIR 模型中表现出减少 RNV 和促进正常视网膜血管恢复的良好效果。本研究为进一步了解 RNV 提供了理论基础,并强调了 tFNAs-miR22 作为缺血性视网膜疾病治疗选择的创新性和潜力。

相似文献

1
Tetrahedral framework nucleic acids-based delivery of MicroRNA-22 inhibits pathological neovascularization and vaso-obliteration by regulating the Wnt pathway.基于四面体型核酸框架的 MicroRNA-22 递呈通过调控 Wnt 通路抑制病理性新生血管形成和血管闭塞。
Cell Prolif. 2024 Jul;57(7):e13623. doi: 10.1111/cpr.13623. Epub 2024 Mar 3.
2
Tetrahedral framework nucleic acids inhibit pathological neovascularization and vaso-obliteration in ischaemic retinopathy via PI3K/AKT/mTOR signalling pathway.四面体框架核酸通过 PI3K/AKT/mTOR 信号通路抑制缺血性视网膜病变中的病理性新生血管形成和血管闭塞。
Cell Prolif. 2023 Jul;56(7):e13407. doi: 10.1111/cpr.13407. Epub 2023 Jan 24.
3
Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway.藜芦醇通过靶向 miR-17-5p/HIF-1α/VEGF 通路抑制氧诱导的视网膜病变中的病理性血管生成。
Cell Cycle. 2022 Oct;21(19):2091-2108. doi: 10.1080/15384101.2022.2087277. Epub 2022 Jun 13.
4
Therapeutic effects of tetrahedral framework nucleic acids and tFNAs-miR22 on retinal ischemia/reperfusion injury.四面体核酸框架和 tFNAs-miR22 对视网膜缺血/再灌注损伤的治疗作用。
Cell Prolif. 2024 Nov;57(11):e13695. doi: 10.1111/cpr.13695. Epub 2024 Jul 31.
5
Exosome-mediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis.外泌体介导的抗血管生成肽递送可抑制病理性视网膜血管生成。
Theranostics. 2021 Mar 5;11(11):5107-5126. doi: 10.7150/thno.54755. eCollection 2021.
6
β‑elemene inhibits oxygen‑induced retinal neovascularization via promoting miR‑27a and reducing VEGF expression.β-榄香烯通过促进 miR-27a 和降低 VEGF 表达抑制氧诱导的视网膜新生血管形成。
Mol Med Rep. 2019 Mar;19(3):2307-2316. doi: 10.3892/mmr.2019.9863. Epub 2019 Jan 15.
7
A Novel Hypoxia-inducible Factor 1α Inhibitor KC7F2 Attenuates Oxygen-induced Retinal Neovascularization.一种新型缺氧诱导因子 1α 抑制剂 KC7F2 可减轻氧诱导的视网膜新生血管形成。
Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):13. doi: 10.1167/iovs.63.6.13.
8
Overexpression of miR-181a-5p inhibits retinal neovascularization through endocan and the ERK1/2 signaling pathway.miR-181a-5p 的过表达通过内皮细胞特异性分子 1(endocan)和 ERK1/2 信号通路抑制视网膜新生血管形成。
J Cell Physiol. 2020 Dec;235(12):9323-9335. doi: 10.1002/jcp.29733. Epub 2020 Apr 28.
9
Tetrahedral Framework Nucleic Acids Connected with MicroRNA-126 Mimics for Applications in Vascular Inflammation, Remodeling, and Homeostasis.四面体框架核酸与 miRNA-126 模拟物的连接及其在血管炎症、重塑和动态平衡中的应用。
ACS Appl Mater Interfaces. 2022 May 4;14(17):19091-19103. doi: 10.1021/acsami.1c23869. Epub 2022 Apr 13.
10
Inhibition of pathological retinal neovascularization by semaphorin 3A.信号素3A对病理性视网膜新生血管形成的抑制作用。
Mol Vis. 2013 Jun 27;19:1397-405. Print 2013.

引用本文的文献

1
Targeted siRNA Delivery Against RUNX1 Via tFNA: Inhibiting Retinal Neovascularization and Restoring Vessels Through Dll4/Notch1 Signaling.通过经皮细针穿刺抽吸(tFNA)靶向递送针对RUNX1的小干扰RNA(siRNA):通过Dll4/Notch1信号通路抑制视网膜新生血管形成并恢复血管
Invest Ophthalmol Vis Sci. 2025 Mar 3;66(3):39. doi: 10.1167/iovs.66.3.39.

本文引用的文献

1
Tetrahedral framework nucleic acids inhibit pathological neovascularization and vaso-obliteration in ischaemic retinopathy via PI3K/AKT/mTOR signalling pathway.四面体框架核酸通过 PI3K/AKT/mTOR 信号通路抑制缺血性视网膜病变中的病理性新生血管形成和血管闭塞。
Cell Prolif. 2023 Jul;56(7):e13407. doi: 10.1111/cpr.13407. Epub 2023 Jan 24.
2
miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X.miR-22 通过靶向 MYC 相关因子 X 调控代谢重编程抑制结直肠癌中的 EMT
Dis Markers. 2022 Aug 25;2022:7843565. doi: 10.1155/2022/7843565. eCollection 2022.
3
Modulation of the Crosstalk between Schwann Cells and Macrophages for Nerve Regeneration: A Therapeutic Strategy Based on a Multifunctional Tetrahedral Framework Nucleic Acids System.
调控施万细胞和巨噬细胞之间的串扰促进神经再生:基于多功能四面体核酸系统的治疗策略。
Adv Mater. 2022 Nov;34(46):e2202513. doi: 10.1002/adma.202202513. Epub 2022 Jun 2.
4
Endothelial Cell Tube Formation Assay: An In Vitro Model for Angiogenesis.内皮细胞管形成试验:一种用于血管生成的体外模型。
Methods Mol Biol. 2022;2475:187-196. doi: 10.1007/978-1-0716-2217-9_12.
5
Tetrahedral framework nucleic acids-based delivery of microRNA-155 inhibits choroidal neovascularization by regulating the polarization of macrophages.基于四面体框架核酸的微小RNA-155递送通过调节巨噬细胞极化抑制脉络膜新生血管形成。
Bioact Mater. 2021 Dec 18;14:134-144. doi: 10.1016/j.bioactmat.2021.11.031. eCollection 2022 Aug.
6
VEGF-Trap Modulates Retinal Inflammation in the Murine Oxygen-Induced Retinopathy (OIR) Model.VEGF 受体融合蛋白调节小鼠氧诱导视网膜病变(OIR)模型中的视网膜炎症。
Biomedicines. 2022 Jan 18;10(2):201. doi: 10.3390/biomedicines10020201.
7
Treatment effect of DNA framework nucleic acids on diffuse microvascular endothelial cell injury after subarachnoid hemorrhage.DNA 框架核酸对蛛网膜下腔出血后弥漫性微血管内皮细胞损伤的治疗作用。
Cell Prolif. 2022 Apr;55(4):e13206. doi: 10.1111/cpr.13206. Epub 2022 Feb 21.
8
Tetrahedral Framework Nucleic Acids Can Alleviate Taurocholate-Induced Severe Acute Pancreatitis and Its Subsequent Multiorgan Injury in Mice.四面体框架核酸可减轻牛磺胆酸钠诱导的小鼠重症急性胰腺炎及其随后的多器官损伤。
Nano Lett. 2022 Feb 23;22(4):1759-1768. doi: 10.1021/acs.nanolett.1c05003. Epub 2022 Feb 9.
9
Biological Effect of Differently Sized Tetrahedral Framework Nucleic Acids: Endocytosis, Proliferation, Migration, and Biodistribution.不同尺寸的四面体核酸框架的生物学效应:内吞作用、增殖、迁移和生物分布。
ACS Appl Mater Interfaces. 2021 Dec 8;13(48):57067-57074. doi: 10.1021/acsami.1c20657. Epub 2021 Nov 22.
10
Functionalizing Framework Nucleic-Acid-Based Nanostructures for Biomedical Application.功能化基于框架核酸的纳米结构用于生物医学应用。
Adv Mater. 2022 Nov;34(46):e2107820. doi: 10.1002/adma.202107820. Epub 2022 Feb 20.